Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 10, 2015, Pages 1748-1756

  Grossi, Victoria ^a   Lerer, Trudy ^a   Griffiths, Anne ^b   LeLeiko, Neal ^c   Cabrera, Jose ^d   Otley, Anthony ^e   Rick, James ^f   Mack, David ^g   Bousvaros, Athos ^h   Rosh, Joel ⁱ   Grossman, Andrew ^j   Saeed, Shehzaad ^k   Kay, Marsha ^l   Boyle, Brendan ^m   Oliva Hemker, Maria ⁿ   Keljo, David ^o   Pfefferkorn, Marian ^p   Faubion, William ^q   Kappelman, Michael D ^r   Sudel, Boris ^s   Markowitz, James ^f   Hyams, Jeffrey S ^a   more..

^a Division of Pediatric Infectious Diseases   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HASBRO CHILDREN'S HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e IWK HEALTH CENTRE   (Canada)

^f Children's Medical Center   (United States)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ Goryeb Children's Hospital   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁿ JOHNS HOPKINS HOSPITAL   (United States)

^o CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^p RILEY HOSPITAL FOR CHILDREN   (United States)

^q MAYO CLINIC   (United States)

^r UNIVERSITY OF NORTH CAROLINA   (United States)

^s UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

Anti Tumor Necrosis Factor; IBD; Immunosuppressant; TNF

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; IMMUNOLOGIC FACTOR;

ADOLESCENT; ALLERGIC REACTION; APPENDICITIS; ARTICLE; AUTOIMMUNE LIVER DISEASE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISTOPLASMOSIS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; CLINICAL TRIAL; INFANT; MULTICENTER STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFLIXIMAB; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84941739976     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.04.010     Document Type: Article

References (21)

1. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873. quiz 1165-1166.
2. de Ridder L., Benninga M.A., Taminiau J.A., et al. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2006, 43:388-390.
3. Church P.C., Guan J., Walters T.D., et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014, 20:1177-1186.
4. Vahabnezhad E., Rabizadeh S., Dubinsky M.C. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014, 20:606-613.
5. Walters T.D., Kim M.O., Denson L.A., et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014, 146:383-391.
6. Hyams J., Walters T.D., Crandall W., et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011, 27:651-662.
7. Hyams J.S., Lerer T., Griffiths A., et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
8. De Bie C.I., Hummel T.Z., Kindermann A., et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011, 33:243-250.
9. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
10. Chaparro M., Panes J., Garcia V., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
11. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
12. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
13. Dulai P.S., Thompson K.D., Blunt H.B., et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014, 12:1443-1451.
14. Dulai P.S., Siegel C.A., Dubinsky M.C. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:2927-2936.
15. Siegel C.A., Finlayson S.R., Sands B.E., et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol 2012, 10:46-51.
16. Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41 e1.
17. Turner D., Grossman A.B., Rosh J., et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007, 102:2804-2812. quiz 2803, 2813.
18. Sunseri W., Hyams J.S., Lerer T., et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease. Inflamm Bowel Dis 2014, 20:1341-1345.
19. Feagan B.G., McDonald J.W., Panaccione R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014, 146:681-688 e1.
20. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
21. Ruperto N., Lovell D.J., Cuttica R., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007, 56:3096-3106.